Trials to slow progression and prevent disease onset

  • L. J. Thal
Conference paper


Current treatments for Alzheimer’s disease (AD) are largely symptomatic and improve cognition. Only a single trial of selegiline and vitamin E has been demonstrated to delay progression of the time to clinically important endpoints in this disease. Effective treatments currently under development are designed to either slow the rate of progression or delay the time of onset. Classes of agents currently being investigated include: antioxidants, anti-inflammatory agents, growth factors, hormones, and drugs designed to prevent the deposition or enhance the removal of amyloid. In addition to trials designed to slow the rate of progression, several primary prevention trials have already been initiated. Finally, a series of trials designed to prevent the development of AD in patients with mild cognitive impairment have been initiated.


Nerve Growth Factor Mild Cognitive Impairment Alzheimer Type Primary Prevention Trial Ginkgo Biloba Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas PG, Weiner MF, Farlow MR, Sano M, Grundman M, Thai LJ (for the Members of the Alzheimer’s Disease Cooperative Study) (2000) A randomized controlled trial of prednisone in Alzheimer’s disease. Neurology 54: 588 – 593Google Scholar
  2. Behl C, Davis J, Cole GM, et al (1992) Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem Biophys Res Commun 186: 944 – 950Google Scholar
  3. Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial. J Am Geriatr Soc 41: 1219 – 1225PubMedGoogle Scholar
  4. Day-Lollini PA, Stewart GR, Taylor MJ, Johnson RM, Chellman GJ (1997) Hyperplastic changes with the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor. Exp Neurol 145: 24 – 37PubMedCrossRefGoogle Scholar
  5. Dekker AJ, Gage FH, Thai LJ (1992) Delayed treatment with nerve growth factor improves acquisition of a spatial task in rats with lesions of the nucleus basalis magnocellularis: Evaluation of involvement of different neurotransmitter systems. Neuroscience 48: 111 – 119PubMedCrossRefGoogle Scholar
  6. Fillit H, Weinreb H, Cholst I, et al (1986) Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer’s type. Psychoneuroendocrinology 11: 337 – 345PubMedCrossRefGoogle Scholar
  7. Fisher W, Wictorin K, Bjorklund A, et. al. (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65 – 68CrossRefGoogle Scholar
  8. Freedman M, Rewilak D, Xerri T, et. al. (1998) L-deprenyl in Alzheimer’s diseaseGoogle Scholar
  9. Cognitive and behavioral effects. Neurology 50: 660–668Google Scholar
  10. Gillis JC, Benfield P, McTravish D (1994) Idebenone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5: 133 – 152PubMedCrossRefGoogle Scholar
  11. Glasky AJ, Ritzmann RF, Prisecaru I, et al (1996) Elevation of brain mRNA for neurotrophins by oral AIT-082 in mice. Soc Neurosci 22: 751 Halliwell B, Gutteridge JMC (1985) Oxygen radicals in the nervous system. Trends Neurosci 8: 22 – 26Google Scholar
  12. Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 14: 2155 – 2162Google Scholar
  13. Hofferberth B (1994) The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215 – 222CrossRefGoogle Scholar
  14. Honjo H, Ogino Y, Naitoh K, et al (1989) In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer’s type). J Steroid Biochem Mol Biol 34: 521 – 525Google Scholar
  15. Jonhagen M, Wahlund LO, Amberla K, et al (1996) Nerve growth factors as a treatment of Alzheimer’s disease. Neurobiol Aging 17: S160 – 161CrossRefGoogle Scholar
  16. LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, for the North American EGb Study Group (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo Biloba for dementia. JAMA 278: 1327 – 1332PubMedCrossRefGoogle Scholar
  17. Maurer K, Ihl R, Dierks T, Frolich L (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 31: 645 – 655PubMedCrossRefGoogle Scholar
  18. Murphy TH, Schnaar Rl, Coyle JT (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4: 1624 – 1633PubMedGoogle Scholar
  19. Ohkura T, Isse K, Akazawa K, et al (1994) Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrinology J 41: 361 – 371Google Scholar
  20. Olson L (1993) NGF and the treatment of Alzheimer’s disease. Exp Neurol 124: 5 – 15PubMedCrossRefGoogle Scholar
  21. Packer L, Haramaki N, Kawabata T, et al (1995) Ginkgo biloba extract (EGb 761). In: Christen Y, Courtois Y, Droy-Lefaix MT (eds), Effect of Ginkgo Biloba extract (EGb 761 ) on aging and age-related disorders. Elsevier, Paris: 23 – 47Google Scholar
  22. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303 – 308PubMedCrossRefGoogle Scholar
  23. Rogers J, Kirby LC, Hempelman SR, et al (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43: 1609 – 1611PubMedGoogle Scholar
  24. Salmon DP, Thai LJ, N B, Heindel WC (1990) Longitudinal evaluation of dementia of the Alzheimer type: a comparison of three standardized mental status examinations. Neurology 40: 1225 – 1230PubMedGoogle Scholar
  25. Sano M, Ernesto C, Thomas RG, et al (1997) A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216 – 1222PubMedCrossRefGoogle Scholar
  26. Schenk D, Barbour R, Dunn W, et al (1999) Immunization with Aβ attenuates Alzheimer’s disease-like pathology in the PDAPP mouse. Nature 400: 173 – 177PubMedCrossRefGoogle Scholar
  27. Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al (1992) Idebenone in senile dementia of Alzheimer type: A multicentre study. Arch Gerontol Geriatr 15: 249 – 260PubMedCrossRefGoogle Scholar
  28. Stern RG, Mohs RC, Davidson M, et al (1994) A longitudinal study of Alzheimer’s disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatr 151: 390 – 396PubMedGoogle Scholar
  29. Thai LJ, Carta A, Clarke WR, et al (1996) A one-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer’s disease. Neurology 47: 705 – 711Google Scholar
  30. Weyer G, Erzigkeit H, Hadler D, Kubick S (1996) Efficacy and safety of idebenone in the long-term treatment of Alzheimer’s disease: A double-blind, placebo-controlled multicentre study. Hum Psychopharmacol 11: 53 – 65CrossRefGoogle Scholar
  31. Winkler J, Ramirez GA, Kuhn G, et al (1997) Reversible induction of Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in vivo after continuous intracerebroventricular administration of nerve growth factor. Ann Neurol 41: 82 – 93PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2000

Authors and Affiliations

  • L. J. Thal
    • 1
  1. 1.Department of NeurosciencesUniversity of California San Diego School of MedicineLa JollaUSA

Personalised recommendations